Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab

Cancer Management and Research

Volumn 6, Issue 1, 2013, Pages

  Sorscher, Steven ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HER 2 overexpression; Metastatic gallbladder adenocarcinoma; Trastuzumab

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER GROWTH; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER METASTASIS; LOADING DRUG DOSE; MEDICAL HISTORY; MIDDLE AGED; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME;

EID: 84890333881     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S55091     Document Type: Article

References (11)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13): 3159-3167.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-137.
3. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2: 37-42.
4. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
5. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(8742): 687-697.
6. Valle J, Wasan H, Palmer DH, et al. Cisplatinum plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273-1281.
7. Aishima SI, Tagucki KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002; 40(3): 269-278.
8. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract. 2001; 197(2): 95-100.
9. Ukita Y, Kato M, Tereda T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (Her-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 2002; 36(6): 780-785.
10. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinical pathologic and prognostic significance of EGFR, VEGF and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008; 98(2): 418-425.
11. Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol. 2012; 30(27): 3271-3273.